|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies.
|
30114705 |
2018 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activation of <i>G0S2</i> is coordinated by recruitment of PML/RARα and C/EBPε to its promoter during ATRA-induced APL differentiation.
|
27605212 |
2017 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
The t(15;17) translocation generates a PML-RARα fusion protein causative for acute promyelocytic leukemia (APL).Li et al. now identify the pseudokinase stress protein TRIB3 as an important factor in APL disease progression and therapy resistance.
|
28486101 |
2017 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
|
28129653 |
2017 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
PML nuclear body disruption impairs DNA double-strand break sensing and repair in APL.
|
27468685 |
2016 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
APL is characterized by a balanced reciprocal chromosomal translocation fusing the promyelocytic leukaemia (PML) gene on chromosome 15 with the retinoic acid receptor α (RARα) gene on chromosome 17.
|
26058416 |
2015 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
APL is the first example of differentiation therapy targeted to a defined genetic target i.e.PML-RARα.
|
24907012 |
2014 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
|
25258343 |
2014 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Establishment of a humanized APL model via the transplantation of PML-RARA-transduced human common myeloid progenitors into immunodeficient mice.
|
25369030 |
2014 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study describes the prognostic significance of quantification of the PML-RARa transcript in children with APL.
|
22407853 |
2012 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gain or loss of genes plays important roles in leukemogenesis of APL via cooperation with PML-RARA.
|
21544632 |
2012 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
APL is most commonly caused by a translocation (15:17) and expression of the promyelocytic leukemia and the retinoic receptor α (PML-RARA) fusion product; however, the events that cooperate with PML-RARA in APL pathogenesis are not well understood.
|
21436577 |
2011 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Masked t(15;17) APL with the insertion of PML-RARalpha fusion gene in 4q21.
|
19477514 |
2009 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The NPM-RAR fusion protein associated with the t(5;17) variant of APL does not interact with PML.
|
16504291 |
2006 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
PML a target of translocations in APL is a regulator of cellular senescence.
|
12357343 |
2002 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
APL is associated with a reciprocal chromosomal translocation of chromosomes 15 and 17, which results in a fusion protein comprising PML and the retinoic acid receptor alpha.
|
11704850 |
2001 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
We described previously an APL case with an unbalanced t(5;17) implicating RARA but neither PML nor PLZF.
|
10360373 |
1999 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All-trans retinoic acid probably induces differentiation of atypical promyelocytes and clinical remission in APL patients by binding to the ligand binding domain (LBD) of the RARa portion of the PML-RARa chimeric protein.
|
10553155 |
1999 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RT-PCR methods have been developed, to date, by various groups to amplify the PML-RARA fusion gene produced by the t(15;17) in APL patients.
|
9737682 |
1998 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
|
9462740 |
1998 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results demonstrate involvement of nuclear receptor corepressor/histone deacetylase complex in the molecular pathogenesis of APL and provide an explanation for differential sensitivities of PML- and PLZF-RARalpha-associated leukemias to ATRA.
|
9531570 |
1998 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
APL is characterized cytogenetically by a t(15;17) translocation which involves both the PML gene on chromosome 15 and the RARa gene on chromosome 17 and gives rise to the PML/RARa fusion protein.
|
7825969 |
1995 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
APL is also associated with a specific chromosomal translocation t(15;17) which fuses the retinoic acid receptor alpha (RAR alpha) gene with a chromosome 15q locus, PML.
|
7719245 |
1995 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
APL is characterized cytogenetically by a t(15;17) translocation which involves both the PML gene on chromosome 15 and the RAR alpha gene on chromosome 17 and gives rise to the PML/RAR alpha fusion protein.
|
8535190 |
1995 |
|
ATRICHIA WITH PAPULAR LESIONS
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Neither the choice of PML intron nor the expression of the 17q- derivative could be correlated with the microgranular variant of APL (M3V), overall survival rate, age, sex or presence of coagulopathy.
|
1486033 |
1992 |